Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

More... (http://www.news-medical.net/news/20130109/Moffitt-Cancer-Center-initiates-PV-10-Phase-1-study-in-melanoma.aspx)